Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)
NCT07908316
This study is recruiting at 9 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of the study is to assess the pharmacokinetics of maridebart cafraglutode after switching from weekly GLP-1RA in participants living with overweight or obesity.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Obesity
- Overweight
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Amgen
- Last updated on ClinicalTrials.gov
- November 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Arizona Research Center · Phoenix, AZ
California · 1
- Catalina Research Institute LLC (CRI) - Montclair · Montclair, CA
Florida · 3
- Fortrea Clinical Research Unit - Daytona Beach · Daytona Beach, FL
- AGA Clinical Trials · Hialeah, FL
- K2 Medical Research Orlando · Maitland, FL
Kentucky · 1
- The Alliance for Multispecialty Research - Lexington · Lexington, KY
Tennessee · 1
- Alliance for Multispecialty Research - Knoxville · Knoxville, TN
Texas · 1
- Fortrea Clinical Research Unit - Dallas · Dallas, TX
Wisconsin · 1
- Fortrea Clinical Research Unit Inc. - Madison · Madison, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.